Non-malignant respiratory illness associated with exposure to arsenic compounds in the environment.

Deepa Gandhi, Sneha Bhandari, Sehal Mishra, Rajnarayan R Tiwari, Subbiah Rajasekaran

Journal: Environmental toxicology and pharmacology 2022;94():103922

PMID: 35779705

Abstract

Arsenic (As), a toxic metalloid, primarily originates from both natural and anthropogenic activities. Reports suggested that millions of people globally exposed to high levels of naturally occurring As compounds via inhalation and ingestion. There is evidence that As is a well-known lung carcinogen. However, there has been relatively little evidence suggesting its non-malignant lung effects. This review comprehensively summarises current experimental and clinical studies implicating the association of As exposure and the development of several non-malignant lung diseases. Experimental studies provided evidence that As exposure induces redox imbalance, apoptosis, inflammatory response, epithelial-to-mesenchymal transition (EMT), and affected normal lung development through alteration of the components of intracellular signaling cascades. In addition, we also discuss the sources and possible mechanisms of As influx and efflux in the lung. Finally, current experimental studies on treatment strategies using phytochemicals and our perspective on future research with As are also discussed.

Copyright © 2022 Elsevier B.V. All rights reserved.

Address: Department of Biochemistry, ICMR-National Institute for Research in Environmental, Health, Bhopal, Madhya Pradesh, India.; Department of Biochemistry, ICMR-National Institute for Research in Environmental, Health, Bhopal, Madhya Pradesh, India. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.